Thanks. Considering Roche and Pfizer are actively pursuing endometrial combo trials, I wonder if it has more to do with the lack of a PI3K inhibitor in MRK's pipeline.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.